Abstract
Objectives: To investigate the clinical characteristics of adverse events (AEs) after COVID-19 vaccination in patients in South Korea.
Design: Data from the Korean Disease Control and Prevention Agency on AEs from 4 COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26, 2021, to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.
Results: Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 AEs were reported. Most AEs occurred after the first dose (80.6%) and within a day (63.2%) after vaccination. Of the AEs, 95.5% were nonsevere cases; however, 4.5% were severe. Most mild AEs showed a similar frequency across all age groups, but major severe AEs and mortality events increased with age.
Conclusions: Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in using all 4 COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted.
Keywords: COVID-19 vaccines; SARS-CoV-2; adverse events; vaccine reactions.
【저자키워드】 SARS-CoV-2, adverse events, COVID-19 vaccines, vaccine reactions, 【초록키워드】 COVID-19, Vaccine, vaccination, Mortality, Clinical symptoms, Clinical characteristics, mRNA-1273, severity, prevention, BNT162b2, AZD1222, Characteristics, COVID-19 vaccination, adverse event, Research, Patient, Control, Mild, complications, age, epidemiological, South Korea, Pfizer-BioNTech, Korean, Frequency, dose, Adverse reaction, Reactions, caution, first dose, individual, study period, all age groups, MOST, JNJ-78436735, event, Occurrence, analyzed, occurred, reported, conducted, AEs, severe AE, were assessed, 【제목키워드】 COVID-19 vaccination, South Korea, Adverse, event,